Literature DB >> 19874253

Vildagliptin in clinical practice: a review of literature.

Moulinath Banerjee1, Naveed Younis, Handrean Soran.   

Abstract

Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19874253     DOI： 10.1517/14656560903302265

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Authors:  Roberta Baetta; Alberto Corsini
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 2.  Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Yuzo Yano; Taku Tsunoda; Takashi Ikawa; Toshihiro Matsuo; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Exp Med       Date:  2015-05-20

Review 3.  Vildagliptin: a review of its use in type 2 diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 4.  Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

5.  Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.

Authors:  Kyoko Kudo-Fujimaki; Takahisa Hirose; Tomoaki Yoshihara; Fumihiko Sato; Yuki Someya; Chie Ohmura; Akio Kanazawa; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2013-11-05       Impact factor: 4.232

6.  DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.

Authors:  Sivaporn Sivasinprasasn; Pongpan Tanajak; Wanpitak Pongkan; Wasana Pratchayasakul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

7.  Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.

Authors:  Cy Pan; Xl Wang
Journal:  Ther Clin Risk Manag       Date:  2013-05-24       Impact factor: 2.423

Review 8.  Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.

Authors:  Hiroyuki Konya; Yuzo Yano; Satoshi Matsutani; Taku Tsunoda; Takashi Ikawa; Yoshiki Kusunoki; Toshihiro Matsuo; Masayuki Miuchi; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  Ther Clin Risk Manag       Date:  2014-07-11       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.